ArticleViruses2016
Development of Neutralization Assay Using an eGFP Chikungunya Virus.
Article in Viruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Glutamine antagonist DON attenuates chikungunya virus-induced myositis by suppressing inflammatory activation in a murine model.Emerging microbes & infections · 2026Article
- A nanoluciferase-expressing attenuated CHIKV vaccine strain enables rapid and visual drug screeningJournal of virology · 2026Article
- Chikungunya Virus E2 N218K Enhances Heparan Sulfate-Dependent Attachment and Viral Internalization While Conferring Partial Attenuation in A129 Mice.Pathogens (Basel, Switzerland) · 2026Article
- Aglycone Polyether Ionophores Affecting Actin Filaments as Broad-Spectrum Antiviral Agents.ACS pharmacology & translational science · 2025Article
- Reporter-expressing viruses for antiviral drug discovery research.Frontiers in cellular and infection microbiology · 2025Review
- A single dose recombinant AAV based CHIKV vaccine elicits robust and durable protective antibody responses in mice.PLoS neglected tropical diseases · 2024Article
- Development and validation of Mayaro virus with luciferase reporter genes as a tool for antiviral assays.Heliyon · 2024Article
- A high throughput antiviral screening platform for alphaviruses based on Semliki Forest virus expressing eGFP reporter gene.Virologica Sinica · 2023Article
- High-Titer Self-Propagating Capsidless Chikungunya Virus Generated in Vero Cells as a Strategy for Alphavirus Vaccine Development.Journal of virology · 2022Article
- A high-dose inoculum size results in persistent viral infection and arthritis in mice infected with chikungunya virus.PLoS neglected tropical diseases · 2022Article
- Evaluation of Structurally Distorted Split GFP Fluorescent Sensors for Cell-Based Detection of Viral Proteolytic Activity.Sensors (Basel, Switzerland) · 2020Article
- Generation of a reporter yellow fever virus for high throughput antiviral assays.Antiviral research · 2020Article
- Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening.Antiviral research · 2020Article
- Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.Journal of virology · 2019Article
- Visualization of chikungunya virus infectionEmerging microbes & infections · 2019Article
- Review
- Detection, isolation, and characterization of chikungunya viruses associated with the Pakistan outbreak of 2016-2017.Virologica Sinica · 2017Article
- Development of a novel Newcastle disease virus (NDV) neutralization test based on recombinant NDV expressing enhanced green fluorescent protein.Virology journal · 2017Article
- Meeting report: the 4Zoological research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV), a member of the Alphavirus genus, is an important human emerging/re-emerging pathogen. Currently, there are no effective antiviral drugs or vaccines against CHIKV infection. Herein, we construct an infectious clone of CHIKV and an eGFP reporter CHIKV (eGFP-CHIKV) with an isolated strain (assigned to Asian lineage) from CHIKV-infected patients. The eGFP-CHIKV reporter virus allows for direct visualization of viral replication through the levels of eGFP expression. Using a known CHIKV inhibitor, ribavirin, we confirmed that the eGFP-CHIKV reporter virus could be used to identify inhibitors against CHIKV. Importantly, we developed a novel and reliable eGFP-CHIKV reporter virus-based neutralization assay that could be used for rapid screening neutralizing antibodies against CHIKV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.